Medtronic (NYSE:MDT) touted a clinical trial it said showed a 46% reduction in atrial fibrillation among patients using the Vivo line of cardiac resynchronization therapy-defibrillators featuring its AdaptivCRT feature.
AdaptivCRT "continually adjusts therapy to a patient’s natural heart rhythms and minimizes the amount of unnecessary right ventricular pacing," according to a press release.
Patients in the study were 34% less likely to need RV pacing than patients undergoing conventional CRT, Fridley, Minn.-based Medtronic said. The AdaptivCRT cohort was also 46% less likely to spend more than 48 hours in a row in atrial fibrillation than the control group, according to the study, presented today at the Heart Failure Society of America’s annual meeting.
Earlier data showed that the AdaptivCRT feature cut overall heart failure hospitalizations by 21% after a year,
"The AdaptivCRT technology is a novel approach to CRT-D that continually and automatically adjusts the therapy to the heart rhythm for each individual patient," Medtronic’s heart failure division general manager Dr. David Steinhaus said in prepared remarks. Steinhaus is also medical director for Medtronic’s cardiac rhythm disease managements business. "The results of the Adaptive CRT trial will be significant as the ‘baby boomer’ population ages and becomes more vulnerable to heart failure and associated conditions such as atrial fibrillation."
Medtronic’s Viva devices won CE Mark approval in the European Union last year and 510(k) clearance from the FDA earlier this year.